Alzheimer's Disease in Down Syndrome.

No abstract is available for this paper.

• Publication year

  2012

• Venue

  European journal of neurodegenerative disease

• Publication date

  2012-12-01

• Fields of study

  Medicine, Psychology

• Identifiers
  PMID 25285303PMCID PMC4184282
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Prevalence and incidence of myocardial infarction and cerebrovascular accident in ageing persons with intellectual disability.

  2013cited by this paper
• Aging and Down Syndrome

  2012cited by this paper
• White matter integrity and vulnerability to Alzheimer's disease: preliminary findings and future directions.

  2012cited by this paper
• Neuroinflammation in the Aging Down Syndrome Brain; Lessons from Alzheimer's Disease

  2012cited by this paper
• Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.

  2012cited by this paper
• Down syndrome with and without dementia: An in vivo proton Magnetic Resonance Spectroscopy study with implications for Alzheimer's disease

  2011cited by this paper
• Plasma Amyloid-β as a Function of Age, Level of Intellectual Disability, and Presence of Dementia in Down Syndrome

  2011cited by this paper
• Risk factors and preventive interventions for Alzheimer disease: state of the science.

  2011cited by this paper
• Epidemiology of Alzheimer disease

  2011cited by this paper
• Microglial pathology in Down syndrome

  2011cited by this paper
• Health conditions associated with aging and end of life of adults with Down syndrome.

  2010cited by this paper
• Change in plasma Aβ peptides and onset of dementia in adults with Down syndrome

  2010cited by this paper
• Meta-analysis of Alzheimer's disease risk with obesity, diabetes, and related disorders.

  2010cited by this paper
• Cerebral amyloid angiopathy as a cause of an extensive brain hemorrhage in adult patient with Down's syndrome - a case report.

  2010cited by this paper
• Comparison of intima-media thickness of the carotid artery and cardiovascular disease risk factors in adults with versus without the Down syndrome.

  2010cited by this paper
• Upregulation of phosphorylated alphaB-crystallin in the brain of children and young adults with Down syndrome.

  2009cited by this paper
• Clinical evaluation of dementia in Down's syndrome: a preliminary report.

  2008cited by this paper
• Neuroimaging of individuals with Down's syndrome at-risk for dementia: Evidence for possible compensatory events

  2008cited by this paper
• Lipids and lipoproteins in persons with Down's syndrome.

  2008cited by this paper
• Selective attention deficits associated with mild cognitive impairment and early stage Alzheimer's disease in adults with Down syndrome.

  2008cited by this paper
• Association between the interleukin-1beta polymorphisms and Alzheimer's disease: a systematic review and meta-analysis.

  2008cited by this paper
• Executive dysfunction and its association with personality and behaviour changes in the development of Alzheimer's disease in adults with Down syndrome and mild to moderate learning disabilities.

  2008cited by this paper
• The four ages of Down syndrome.

  2007cited by this paper
• Alpha- and beta-secretase activity as a function of age and beta-amyloid in Down syndrome and normal brain.

  2007cited by this paper
• Trisomy-driven overexpression of DYRK1A kinase in the brain of subjects with Down syndrome.

  2007cited by this paper
• Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease.

  2006cited by this paper
• Improved national prevalence estimates for 18 selected major birth defects--United States, 1999-2001.

  2006cited by this paper
• APP locus duplication causes autosomal dominant early-onset Alzheimer disease with cerebral amyloid angiopathy

  2006cited by this paper
• The 9 year cognitive decline before dementia of the Alzheimer type: a prospective population-based study.

  2005cited by this paper
• Dementia of the Alzheimer's type and accelerated aging in Down syndrome.

  2005cited by this paper
• Stability and change in cognitive ability over the life span: a comparison of populations with and without Down's syndrome.

  2005cited by this paper
• Efficacy of proton magnetic resonance spectroscopy in neurological diagnosis and neurotherapeutic decision making

  2005cited by this paper
• Prevalence of dementia in adult patients with trisomy 21.

  2005cited by this paper
• Down syndrome and beta-amyloid deposition

  2004cited by this paper
• Abeta localization in abnormal endosomes: association with earliest Abeta elevations in AD and Down syndrome.

  2004cited by this paper
• Down's syndrome.

  2003cited by this paper
• Looking into the functional architecture of the brain with diffusion MRI

  2003cited by this paper
• Temporal cortex hypermetabolism in Down syndrome prior to the onset of dementia

  2003cited by this paper
• Maladaptive behaviours and symptoms of dementia in adults with Down's syndrome compared with adults with intellectual disability of other aetiologies.

  2002cited by this paper
• Incidence and temporal patterns of adaptive behavior change in adults with mental retardation.

  2002cited by this paper
• The changing survival profile of people with Down's syndrome: implications for genetic counselling

  2002cited by this paper
• Genetic and host factors for dementia in Down's syndrome.

  2002cited by this paper
• Diffusion tensor imaging and aging – a review

  2002cited by this paper
• Intraneuronal Abeta42 accumulation in Down syndrome brain.

  2002cited by this paper
• The Amyloid Hypothesis of Alzheimer's Disease: Progress and Problems on the Road to Therapeutics

  2002cited by this paper
• The basis of anisotropic water diffusion in the nervous system – a technical review

  2002cited by this paper
• Incidence and course of dementia in people with Down's syndrome: findings from a population-based study.

  2001cited by this paper
• Complement association with neurons and beta-amyloid deposition in the brains of aged individuals with Down Syndrome.

  2001cited by this paper
• Dementia in people with Down's syndrome

  2001cited by this paper
• In vivo fiber tractography using DT‐MRI data

  2000cited by this paper
• Sequence of cognitive decline in dementia in adults with Down's syndrome.

  2000cited by this paper
• Lectin-histochemical detection of degenerative glycoconjugate deposits in human brain.

  2000cited by this paper
• Inflammation and Alzheimer's disease.

  2000cited by this paper
• Neuronal oxidative stress precedes amyloid-beta deposition in Down syndrome.

  2000cited by this paper
• Endocytic pathway abnormalities precede amyloid beta deposition in sporadic Alzheimer's disease and Down syndrome: differential effects of APOE genotype and presenilin mutations.

  2000cited by this paper
• Prevalence of dementia and impact on intellectual disability services.

  2000cited by this paper
• Down's syndrome is associated with increased 8,12‐iso‐iPF2α‐VI levels: Evidence for enhanced lipid peroxidation in vivo

  2000cited by this paper
• Temporal accrual of complement proteins in amyloid plaques in Down's syndrome with Alzheimer's disease.

  2000cited by this paper
• High brain myo-inositol levels in the predementia phase of Alzheimer's disease in adults with Down's syndrome: a 1H MRS study.

  1999cited by this paper
• A four year prospective study of age-related cognitive change in adults with Down's syndrome

  1998cited by this paper
• Early glycoxidation damage in brains from Down's syndrome.

  1998cited by this paper
• Early amyloid deposition in the medial temporal lobe of young Down syndrome patients: a regional quantitative analysis.

  1998cited by this paper
• Dementia in adults with Down syndrome: diagnostic challenges.

  1998cited by this paper
• Prospective study of the prevalence of Alzheimer-type dementia in institutionalized individuals with Down syndrome.

  1997cited by this paper
• Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia.

  1997cited by this paper
• Diagnosis of dementia in individuals with intellectual disability.

  1997cited by this paper
• Further evaluation of the Dementia Questionnaire for Persons with Mental Retardation (DMR).

  1996cited by this paper
• Prevalence of dementia in adults with and without Down syndrome.

  1996cited by this paper
• Cerebral amyloid deposition and diffuse plaques in ``normal'' aging

  1996cited by this paper
• Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.

  1996cited by this paper
• Mortality of people with mental retardation in California with and without Down syndrome, 1986-1991.

  1996cited by this paper
• Low blood pressure in Down's syndrome, A link with Alzheimer's disease?

  1996cited by this paper
• Brain cognition and metabolism in Down syndrome adults in association with development of dementia

  1996cited by this paper
• Behavioural disturbance in people with Down's syndrome and dementia.

  1995cited by this paper
• Detection of Alzheimer disease in individuals with Down syndrome.

  1995cited by this paper
• Variability of beta-amyloid protein deposited lesions in Down's syndrome brains.

  1994cited by this paper
• Mental disorders and adaptive behaviour in people with Down's syndrome

  1993cited by this paper
• Ubiquitin‐immunoreactive Dystrophic Neurites in Down's Syndrome Brains

  1991cited by this paper
• The natural history of dementia in Down's syndrome.

  1990cited by this paper
• Regional Cerebral Glucose Metabolism is Normal in Young Adults with down Syndrome

  1990cited by this paper
• The pattern of acquisition of plaques and tangles in the brains of patients under 50 years of age with Down's syndrome.

  1989cited by this paper
• A prospective study of Alzheimer disease in Down syndrome.

  1989cited by this paper
• Amyloid A4 protein and its precursor in Down's syndrome and Alzheimer's disease.

  1989cited by this paper
• Dementia in Down's syndrome

  1988cited by this paper
• Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome.

  1986cited by this paper
• Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome

  1985cited by this paper
• Altered Composition of Polyunsaturated Fatty Acyl Groups in Phosphoglycerides of Down's Syndrome Fetal Brain

  1985cited by this paper
• Down's syndrome in adults: brain metabolism.

  1983cited by this paper
• Synaptic density in human frontal cortex - developmental changes and effects of aging.

  1979cited by this paper
• Precocious aging and dementia in patients with Down's syndrome.

  1978cited by this paper
• Down's syndrome: an atheroma-free model?

  1977cited by this paper
• The density of synapses and neurons in normal, mentally defective ageing human brains.

  1975cited by this paper
• Alzheimer's disease in Down's syndrome: visual retention deficits.

  1974cited by this paper
• Alzheimer's disease in Down's syndrome.

  1971cited by this paper
• [Study of somatic chromosomes from 9 mongoloid children].

  1959cited by this paper

• The cholinergic system exerts opposing effects on memory at different stages of disease progression in Alzheimer's and Down syndrome model systems

  2026cites this paper
• Insulin Signaling in Alzheimer’s Disease: Association with Brain Insulin Resistance

  2026cites this paper
• Diagnostic Paper‐Pencil Instruments for Dementia in People With Intellectual Disability: Scoping Literature Review

  2025cites this paper
• Opposing interictal dynamics in Alzheimer's disease and epilepsy.

  2025cites this paper
• Advancing inclusive brain health and dementia care for people with intellectual and developmental disabilities: a public health framework

  2025cites this paper
• Proactive Cognitive Stimulation for Younger Adults With Down Syndrome. A Feasibility Randomised Control Trial.

  2025cites this paper
• Bridging Health Disparity Gaps in Alzheimer’s Disease among Marginalized Populations: Clinical Proteomics as a Case Study

  2025cites this paper
• Restoring DSCAM expression rescues neuronal morphology and axon guidance deficits in Down syndrome

  2025cites this paper
• U1‐70K and U1A and tau pathogenesis in demented and non‐demented individuals with Down syndrome

  2025cites this paper
• High‐frequency oscillations >250 Hz in people with Down syndrome and associated Alzheimer's disease dementia

  2025cites this paper
• Leptin levels are associated with body mass index and Alzheimer's disease in Down syndrome

  2025cites this paper
• Gait variability as a marker of white matter integrity in individuals with Down syndrome

  2025cites this paper
• Evidence that cholinergic mechanisms contribute to hyperexcitability at early stages in Alzheimer’s disease

  2025cites this paper
• Gut dysbiosis in Down syndrome: A potentially unexplored culprit for early Alzheimer's disease

  2025cites this paper
• Resistance and resilience to Alzheimer's disease in Down syndrome

  2025cites this paper
• Mitochondrial Imbalance in Down Syndrome: A Driver of Accelerated Brain Aging?

  2025cites this paper
• Correlating hippocampal and amygdala volumes with neuropathological burden in Down syndrome and Alzheimer’s disease and related neurodegenerative pathologies using 7T postmortem MRI

  2025cites this paper
• Validity of one‐time assessments for identifying prodromal Alzheimer's disease in adults with Down syndrome

  2025cites this paper
• Early Diagnosis of Alzheimer’s Disease Using Adaptive Neuro K-Means Clustering Technique

  2025cites this paper
• A neuropathology case report of a woman with Down syndrome who remained cognitively stable: Implications for resilience to neuropathology

  2025cites this paper
• Neurodegenerative Biomarkers in Populations with Intellectual Disabilities: Diagnostic and Therapeutic Capacities

  2025cites this paper
• From understanding to action: Exploring molecular connections of Down syndrome to Alzheimer's disease for targeted therapeutic approach

  2024cites this paper
• Short term GABA antagonist treatment improves long term sleep quality, memory, and decision-making in a Down syndrome mouse model.

  2024cites this paper
• Assessing the Benefit of Dietary Choline Supplementation Throughout Adulthood in the Ts65Dn Mouse Model of Down Syndrome

  2024cites this paper
• The association of dementia risk symptoms and functional activity in adults with Down syndrome

  2024cites this paper
• Adult choline supplementation in a Down syndrome model reduces co-morbidities and improves cognition

  2024cites this paper
• Gene-variant specific effects of plasma amyloid-β levels in Swedish autosomal dominant Alzheimer disease

  2024cites this paper
• Reduction in neurons immunoreactive for calcium-binding proteins in the anteroventral thalamic nuclei of individuals with Down syndrome.

  2024cites this paper
• Structural Magnetic Resonance Imaging-Based Surface Morphometry Analysis of Pediatric Down Syndrome

  2024cites this paper
• The reciprocal relationship between amyloid precursor protein and mitochondrial function

  2024cites this paper
• A Neuropathology Case Report of a Woman with Down Syndrome who Remained Cognitively Stable

  2024cites this paper
• Measurement of synaptic density in Down syndrome using PET imaging: a pilot study

  2024cites this paper
• Retromer Stabilization Improves Cognitive Function and Synaptic Plasticity in a Mouse Model of Down Syndrome

  2023cites this paper
• Cerebral organoids with chromosome 21 trisomy secrete Alzheimer’s disease-related soluble aggregates detectable by single-molecule-fluorescence and super-resolution microscopy

  2023cites this paper
• High Frequency Oscillations (>250Hz) Outnumber Interictal Spikes in Preclinical Studies of Alzheimer’s Disease

  2023cites this paper
• Pathways linking pulse pressure to dementia in adults with Down syndrome

  2023cites this paper
• 13 QUO VADIS MODULARITY IN THE 2020 S ?

  2023cites this paper
• Molecular basis of selective amyloid‐β degrading enzymes in Alzheimer's disease

  2023cites this paper
• Intervention of next-generation sequencing in diagnosis of Alzheimer’s disease: challenges and future prospects

  2023cites this paper
• Correlating MRI‐based brain volumetry and cognitive assessment in people with Down syndrome

  2023cites this paper
• Pathological Analysis of down Syndrome and Its Nursing Care

  2023cites this paper
• Examining the prevalence and type of technology-use in people with Down syndrome: Perspectives from parents and caregivers

  2023cites this paper
• Ts65Dn synaptic proteome partially recapitulates AD biochemical signature

  2023cites this paper
• Interictal spikes in Alzheimer’s disease: Preclinical evidence for dominance of the dentate gyrus and cholinergic control by the medial septum

  2023cites this paper
• Outcomes of use of the quality outcome measure for individuals with dementia (QOMID) with people with Down’s syndrome and dementia

  2023cites this paper
• The action of phosphodiesterase-5 inhibitors on β-amyloid pathology and cognition in experimental Alzheimer's disease: A systematic review.

  2023cites this paper
• Toward the Identification of Neurophysiological Biomarkers for Alzheimer’s Disease in Down Syndrome: A Potential Role for Cross-Frequency Phase-Amplitude Coupling Analysis

  2023cites this paper
• Epileptic seizures and link to memory processes

  2022cites this paper
• Spatially resolved neural slowing predicts impairment and amyloid burden in Alzheimer’s disease

  2022cites this paper
• Screening and diagnosing dementia in people with Down’s syndrome: implications of using the DLD questionnaire

  2022cites this paper
• Complement dysregulation and Alzheimer's disease in Down syndrome

  2022cites this paper
• Somatic Mutations and Alzheimer’s Disease

  2022cites this paper
• Multimodal analyses of a non-human primate model harboring mutant amyloid precursor protein transgenes driven by the human EF1α promoter.

  2022cites this paper
• Covalent fragment inhibits intramembrane proteolysis

  2022cites this paper
• Vitamin D3 supplementation may attenuate morphological and molecular abnormalities of the olfactory bulb in a mouse model of Down syndrome.

  2022cites this paper
• Understanding the neurophysiological consequences of Alzheimer’s disease pathology

  2022cites this paper
• Dysfunction of the retromer complex system contributes to amyloid and tau pathology in a stem cell model of Down syndrome

  2022cites this paper
• Pre-visit concerns: What caregivers hope to address at a specialty clinic for down syndrome.

  2022cites this paper
• Neurogenesis and neuronal differentiation in the postnatal frontal cortex in Down syndrome

  2022cites this paper
• Cognitive outcome measures for tracking Alzheimer's disease in Down syndrome.

  2022cites this paper
• Down-syndrome-induced senescence disrupts the nuclear architecture of neural progenitors.

  2022cites this paper
• Evaluation of the Relationship Between Aromatase/Sirtuin1 Interaction and miRNA Expression in Human Neuroblastoma Cells.

  2022cites this paper
• The Challenging Pathway of Treatment for Neurogenesis Impairment in Down Syndrome: Achievements and Perspectives

  2022cites this paper
• Cardiovascular physiology and pathophysiology in Down syndrome.

  2022cites this paper
• Developmental Functioning of Infants and Toddlers with Autism and Down Syndrome

  2022cites this paper
• Temporal and brain region‐specific elevations of soluble Amyloid‐β40‐42 in the Ts65Dn mouse model of Down syndrome and Alzheimer’s disease

  2022cites this paper
• A Review of Functional Neuroimaging in People with Down Syndrome with and without Dementia

  2021cites this paper
• Mental Health, Intellectual and Developmental Disabilities and the Ageing Process

  2021cites this paper
• Commonalities in biomarkers and phenotypes between mild cognitive impairment and cerebral palsy: a pilot exploratory study

  2021cites this paper
• Cerebellar Calcium-Binding Protein and Neurotrophin Receptor Defects in Down Syndrome and Alzheimer's Disease

  2021cites this paper
• Alzheimer's risk and quality of life: History of Down syndrome as a case in point

  2021cites this paper
• Sorting Out Sorting Nexins Functions in the Nervous System in Health and Disease

  2021cites this paper
• Alzheimer's disease: An evolving understanding of noradrenergic involvement and the promising future of electroceutical therapies

  2021cites this paper
• CSF Biomarkers in Down Syndrome and Autosomal Dominant Alzheimer Disease

  2021cites this paper
• Increased excitatory to inhibitory synaptic ratio in parietal cortex samples from individuals with Alzheimer’s disease

  2021cites this paper
• Insulin Resistance as a Common Link Between Current Alzheimer’s Disease Hypotheses

  2021cites this paper
• An Intelligent Healthcare System for Automated Alzheimer's Disease Prediction and Personalized Care

  2021cites this paper
• Automated Fiber Quantification for Alzheimer’s Disease Diagnosis from Neuropsychological Biomarkers

  2021cites this paper
• A novel inhibitor rescues cerebellar defects in a zebrafish model of Down syndrome–associated kinase Dyrk1A overexpression

  2021cites this paper
• A review of the mechanisms underlying selected comorbidities in Alzheimer’s disease

  2021cites this paper
• A qualitative study of the needs of older adults with intellectual disabilities.

  2021cites this paper
• Basal Forebrain Cholinergic Neurons: Linking Down Syndrome and Alzheimer’s Disease

  2021cites this paper
• Epigallocatechin-3-gallate

  2021cites this paper
• Nerve Growth Factor Compromise in Down Syndrome

  2021cites this paper
• Astrocytes in Down Syndrome Across the Lifespan

  2021cites this paper
• Structural magnetic resonance imaging demonstrates volumetric brain abnormalities in down syndrome: Newborns to young adults

  2021cites this paper
• Selective Impairment of Long-Range Default Mode Network Functional Connectivity as a Biomarker for Preclinical Alzheimer’s Disease in People with Down Syndrome

  2021cites this paper
• Psychedelic‐inspired approaches for treating neurodegenerative disorders

  2021cites this paper
• Biological Mechanism-based Neurology and Psychiatry: A BACE1/2 and Downstream Pathway Model

  2021cites this paper
• Development of Down Syndrome Research Over the Last Decades–What Healthcare and Education Professionals Need to Know

  2021cites this paper
• Anxiety and Spatial Navigation in Williams Syndrome and Down Syndrome

  2021cites this paper
• Alzheimer's Disease in Individuals with Down Syndrome

  2021cites this paper
• A HEALTHY DIET TO REDUCE THE RISK OF DEMENTIA IN PEOPLE WITH A LEARNING DISABILITY

  2021cites this paper
• Distribution of microglial phenotypes as a function of age and Alzheimer's disease neuropathology in the brains of people with Down syndrome

  2020cites this paper
• Association Between Plasma Metabolites and Psychometric Scores Among Children With Developmental Disabilities: Investigating Sex-Differences

  2020cites this paper
• Alzheimer’s disease and Down syndrome

  2020cites this paper
• Cognitive indicators of transition to preclinical and prodromal stages of Alzheimer's disease in Down syndrome

  2020cites this paper
• Intellectual Disabilities: A systematic review

  2020cites this paper
• The Role of Alpha-Synuclein and Other Parkinson’s Genes in Neurodevelopmental and Neurodegenerative Disorders

  2020cites this paper
• Correlation of Alzheimer Disease Neuropathologic Staging with Amyloid and Tau Scintigraphic Imaging Biomarkers

  2020cites this paper